Terlipressin

New to peptides? Start with what are peptides? and how do peptides work?

Overview

Terlipressin is a vasopressin analog built around a delivery trick. The molecule itself has relatively weak activity; it carries three extra glycine residues that are gradually cleaved off in the body, steadily releasing the active compound lysine-vasopressin. That makes terlipressin a slow-release prodrug, and it converts vasopressin's brief, spiky action into something sustained enough to give as intermittent injections rather than a continuous infusion.

Built for the failing liver

Terlipressin's clinical identity is tied almost entirely to advanced cirrhosis. In advanced liver disease, the blood vessels supplying the gut — the splanchnic circulation — become abnormally dilated. This has two damaging consequences: blood pools in the abdomen instead of circulating effectively, so the kidneys are underperfused and can fail; and portal pressure rises, engorging the fragile veins in the esophagus until they bleed.

Terlipressin addresses both problems with one action. By constricting the splanchnic vessels, it redirects blood back into the effective circulation, restoring kidney perfusion, and it lowers portal pressure, reducing variceal bleeding.

Availability differs by country

Terlipressin has been standard therapy in Europe and much of the world for decades. In the United States it was not approved until 2022, when it was authorized for hepatorenal syndrome under the brand name Terlivaz. That timing gap explains why older American literature discusses alternatives that other countries had long since moved past.

How it works

Splanchnic-selective vasoconstriction

Terlipressin acts predominantly at V1 receptors, which are densely represented on splanchnic vascular smooth muscle. Its relative preference for V1 over V2 means it produces vasoconstriction with less of the water-retention effect of vasopressin — an important property in patients who are already prone to fluid overload and low sodium.

The hepatorenal cascade

Hepatorenal syndrome is not primarily a kidney disease. The kidneys themselves are often structurally normal. The problem is circulatory: splanchnic vasodilation lowers effective arterial blood volume, the body compensates by activating systems that constrict the renal arteries, and renal blood flow falls until the kidneys fail. Terlipressin interrupts this at the origin. Constricting the splanchnic bed restores effective circulating volume, the compensatory renal vasoconstriction relaxes, and kidney function can recover. Albumin is given alongside it to support plasma volume, which is why the two are almost always used together.

In variceal bleeding

Reducing splanchnic inflow lowers portal venous pressure, and lower pressure in the varices means less force driving the bleed. This buys time and improves conditions for definitive endoscopic treatment such as band ligation.

Why the prodrug design matters

Sustained release avoids the sharp peaks of vasopressin activity that would otherwise cause more severe ischemic effects, and allows administration by intermittent bolus in settings without continuous infusion capability — practically relevant in emergency care.

Clinical uses & evidence

Hepatorenal syndrome

The randomized CONFIRM trial evaluated terlipressin plus albumin against placebo plus albumin in patients with hepatorenal syndrome type 1, the rapidly progressive form. Terlipressin significantly improved the primary endpoint of reversal of the syndrome. That result supported FDA approval, and it also clarified the trade-off: the trial reported more respiratory failure in the terlipressin group, which is why patient selection and fluid management have become central to how the drug is used. Patients with advanced acute-on-chronic liver failure or existing respiratory compromise are recognized as higher risk.

Earlier trials and meta-analyses had already established terlipressin's efficacy in this setting and are the reason it became standard care internationally well before US approval.

Variceal bleeding

Terlipressin is a standard part of acute variceal bleeding management in many countries, given alongside endoscopic therapy and antibiotics. Evidence supports improved control of bleeding, and it has been compared favorably with older vasoactive agents on safety grounds. It is generally used for a short defined course after the acute episode.

Interpreting the evidence

Terlipressin treats conditions with high mortality where the alternatives are limited, so its benefit-risk balance is judged against a grim baseline rather than against a benign one. The honest summary is that it works, that its ischemic and respiratory risks are real and quantified, and that outcomes depend heavily on selecting the right patients — which is precisely the kind of nuance that gets lost when a drug is discussed outside its clinical context.

Forms & how it's given

Terlipressin is given intravenously in a hospital, either as intermittent bolus injections every several hours or as a continuous infusion. Continuous infusion has been associated with fewer adverse effects than bolus dosing in some studies, and practice varies by center and country.

For hepatorenal syndrome, it is given together with intravenous albumin, and treatment continues for a defined period while kidney function is tracked with daily creatinine. Oxygen saturation is monitored because of the respiratory risk, and treatment is stopped if ischemic complications appear or if there is no response within the expected window.

We do not publish dosing protocols. Terlipressin is an inpatient intravenous medicine administered under specialist supervision with continuous monitoring; there is no outpatient or self-administered use.

Safety & legal status

Ischemic complications

Because the drug works by constricting blood vessels, reduced blood flow is the predictable hazard. Reported events include abdominal pain and bowel ischemia, chest pain and myocardial ischemia, and skin or peripheral ischemia including digital discoloration and, rarely, necrosis. Risk rises with dose and with pre-existing vascular disease.

Respiratory and fluid effects

Respiratory failure emerged as a significant concern in the CONFIRM trial and carries specific labeling attention. Patients with volume overload, existing lung disease, or advanced acute-on-chronic liver failure are at higher risk, and careful fluid management alongside albumin is part of mitigating it.

Other effects

• Hyponatremia, since some residual V2 activity remains — sodium is monitored, particularly with rapid drops.
• Bradycardia and arrhythmias.
• Abdominal cramping and diarrhea from increased gut smooth-muscle activity.
• Fluid overload compounded by concurrent albumin administration.

Legal status

Terlipressin is an approved prescription medicine — approved in the US since 2022 for hepatorenal syndrome and long approved elsewhere for that indication and for variceal bleeding. It is supplied to hospitals, has no consumer availability, and is not sold as a research chemical.

Vasopressin and its analogs compared

Natural vasopressin does two unrelated jobs — it makes the kidneys retain water (V2) and constricts blood vessels (V1). Each analog was engineered to isolate one of them, which is why they end up in completely different parts of the hospital.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Wong F. Terlipressin for hepatorenal syndrome. Curr Opin Gastroenterol. 2024. Peer-reviewed study
2. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med. 2021. Peer-reviewed study
3. Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review. JAMA. 2023. Peer-reviewed study
4. Singh S, Chandan S, Vinayek R, et al. Comprehensive approach to esophageal variceal bleeding: From prevention to treatment. World J Gastroenterol. 2024. Peer-reviewed study